Gilead Gets Positive Opinion From European Regulators on Breast-Cancer Treatment

Dow Jones05-22 20:13

By Nicholas G. Miller

Gilead Sciences received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the marketing authorization of its Trodelvy drug to treat breast cancer.

The recommendation focused on the drug as a first-line monotherapy for metastatic triple-negative breast cancer, a type of breast cancer associated with low survival rates, the biotechnology company said.

The European Commission decision on the additional Trodelvy indication is expected later this year, Gilead said.

Gilead has also submitted an application to the U.S. Food and Drug Administration for approval of Trodelvy in this indication, it said.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 22, 2026 08:13 ET (12:13 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment